AMR Dx Use Accelerator
What is this project?
The Antimicrobial Resistance (AMR) Diagnostic (Dx) Use Accelerator is a platform to evaluate a package of interventions and provide evidence to inform policy change that can positively impact AMR and contribute to universal health coverage (UHC).
Why are we working on it?
The AMR Dx Use Accelerator will ultimately help to prepare for the introduction of new diagnostics and provide a safe environment for new antibiotics to enjoy a longer useful therapeutic lifespan. It complements R&D initiatives for both diagnostics and drugs from FIND, GARDP and CARB-X, by ensuring there is a robust downstream mechanism for driving uptake and implementation.
What does it involve?
In the first instance we are focusing on interventions to improve management of patients presenting with fever, by providing and evaluating a “toolbox” that can help healthcare professionals provide more targeted treatments. By adopting available diagnostic tests and other diagnosis aids, and encouraging behaviour changes in outpatient clinics, we hope to rationalize the use of antibiotics.
To generate the data to support this toolbox, we are running two clinical trials in Africa, two in Asia, and one in India.
|Evidence-based practice: PICO framework
Patients: children and adolescents with undifferentiated febrile illness presenting to outpatient clinics / peripheral health centres in low- and middle-income countries
Intervention: available diagnostic tests; diagnostic algorithms/aids; prescriber and user behaviour changes
Control: current practice
Outcomes: improved case management of febrile illnesses; targeted use of antibiotics / reduced antibiotic prescriptions
What do we expect to achieve?
These activities will provide data to inform WHO and in-country policy makers, with the aim of incorporating the toolbox into patient care algorithms.
What is the timescale?
AMR Dx Use Accelerator activities are expected to run for 3 years, between 2018 and 2021.
Partners and funding
The clinical trial in India is being conducted through a partnership with the Indian Council for Medical Research (ICMR). The University of Oxford is supporting us with grant management, and trial monitoring and evaluation. The WHO Special Programme for Research and Training in Tropical Diseases (TDR) is providing technical support, and collaborating with us on study design and implementation.
For more information please contact us.